Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


KINAXO extends collaboration with Takeda


Munich, Germany, March 15, 2011 - KINAXO Biotechnologies GmbH announced today that it has entered a second collaboration with Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout ® to assist in research of drugs under development at Takeda. This will allow Takeda to take early educated decisions on drug efficacy and safety. Financial details of the agreement were not disclosed.

PhosphoScout® enables quantitative analysis of cellular phosphoproteomes on a global scale. Since signal transmission in eukaryotic cells is mainly regulated by reversible protein phosphorylation, comprehensive analysis of phosphoproteome modulation in response to drug treatment provide valuable insights into a drug’s mode of action. Furthermore, PhosphoScout® can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials.

PhosphoScout® utilizes state-of-the-art mass spectrometry methods enabling unbiased quantification of approx. 15,000 phosphorylation sites in a single experiment. Proprietary bioinformatic software tools are applied to visualize the drug’s effects on cellular signal transduction pathway and help identify phospho-protein biomarkers.

Dr. Andreas Jenne, KINAXO’s CEO said: “We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda’s efforts in developing drugs. This collaboration once again demonstrates the power of our PhosphoScout® platform in drug discovery and development.”


About KINAXO - www.kinaxo.com
KINAXO Biotechnologies GmbH, based in Munich/Martinsried, supports pharma companies in developing targeted drugs. Our service offering includes drug mode-of-action analysis, cellular target profiling, target deconvolution, and biomarker discovery.

On February 9, 2011 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced the signing of a definitive agreement to acquire all shares in KINAXO Biotechnologies GmbH. Within Evotec KINAXO will become a centre of excellence for mass spectrometry based chemical proteomics and phosphoproteomics technologies. The acquisition confirms Evotec's leading position as fully integrated drug discovery and early development partner for pharmaceutical and biotechnology companies.


Contact
Dr. Andreas Jenne, CEO
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried
Email: info@kinaxo.de
Phone: +49 89 4613363-11
www.kinaxo.com


Publisher Contact Information:

KINAXO Biotechnologies GmbH
+49 89 4613363-11
info@kinaxo.de

Company profile of KINAXO Biotechnologies GmbH
Past press releases of KINAXO Biotechnologies GmbH.

Data


21,129
Tech investments
From our Online Data Service
13,650
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 15€1.2ME-Commerce
Feb 4€0.5MMedical devices
Feb 4€5.0MMedical devices
Feb 3€22.0MBiopharmaceuticals
Feb 3€1.4MConsumer electronics
Feb 2€0.2MWireless applications
Feb 2€78.0MBiopharmaceuticals

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Feb 2
Spotcap
online lending platform spotcap raises eur 31.5m in funding

Feb 2
Mission Therapeutics
mission therapeutics raises £60 million to progress development of ...

Feb 2
Watchmaster
watchmaster snags $8 mln series b

Jan 21
Endeit Capital
endeit capital holds €125 million final close for new fund

Jan 20
ysura GmbH
ysura lands top talent joern jackowski and enters otc market





About usContact usLegal Information
Copyright © 1999-2016
Emerging Technology Research Europe Inc. All rights reserved.